Sanjay Shukla - Feb 3, 2022 Form 4 Insider Report for aTYR PHARMA INC (LIFE)

Role
President and CEO, Director
Signature
Nancy E. Denyes, attorney-in-fact
Stock symbol
LIFE
Transactions as of
Feb 3, 2022
Transactions value $
$0
Form type
4
Date filed
2/7/2022, 03:52 PM
Previous filing
Jan 10, 2022
Next filing
May 26, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIFE Employee Stock Option (right to buy) Award $0 +83K $0.00 83K Feb 3, 2022 Common Stock 83K $5.52 Direct F1
transaction LIFE Restricted Stock Units Award $0 +41.5K $0.00 41.5K Feb 3, 2022 Common Stock 41.5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 3, 2022, such that this option will be fully exercisable on February 3, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F3 The RSUs are scheduled to vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.